Business Wire

Innovaderm Research Rebrands as Indero, a Dual-Focus CRO

Share

Innovaderm, a leading clinical research organization (CRO), is excited to reveal a major rebranding to Indero, with immediate effect. The new brand identity reinforces the company’s dual focus on rheumatology and dermatology and recognizes the close synergy between these fields.

Innovaderm has over 25 years of clinical research experience within dermatology, and recognizes that many inflammatory and autoimmune conditions manifest across both the skin and the musculoskeletal system. Rheumatology and dermatology therefore often overlap in diagnosing and managing diseases where the immune system plays a central role, and Indero will harness its expertise to deliver comprehensive, patient-focused solutions for these markets. The company’s full-service approach can support both early and late-phase trials across both specialties.

Dr Robert Bissonnette, Founder and Executive Chairman, commented: “As Innovaderm, we have served the dermatology clinical research community for 25 years, building a reputation for quality and excellence. As we move forward as Indero, we will continue to provide the expertise in dermatology that our clients have come to expect from us, while further strengthening our focus on rheumatology and expanding our support within this field. We are excited about the future and supporting the development of new therapies in these two areas of research, ultimately helping to improve patients' health and quality of life.”

Jeff Smith, CEO of Indero, added: “Our dual-focus, interdisciplinary approach allows us to support clinical studies for a wide range of rheumatology and dermatology conditions. The immune-mediated nature of both disease areas means that we are perfectly positioned to support clinical research across these specialties. Our network of investigators and research sites – combined with extensive in-house experience – means that we can support sponsors with the unique requirements of trials in these fields, from difficult-to-find patient populations to complex endpoints. As Indero, we are ‘all in’ with our commitment to providing sponsors with the rigorous scientific foundation and tailored expertise that their studies need.”

Visit www.inderocro.com to explore Indero’s services and expertise.

About Indero

Indero is a dual-focus CRO for dermatology and rheumatology, with over 25 years of experience in clinical research and trial delivery. Our full-service approach – which includes everything from protocol design and patient recruitment to trial monitoring and biometrics – provides biotech and pharmaceutical sponsors with the rigorous scientific foundation and tailored expertise their studies need to reach the finish line efficiently and effectively. With capabilities in the U.S., Canada, Europe, LATAM, and APAC; vast, continuously growing relationships with investigators and patients; and a dedicated research clinic through which we design and execute our own studies, Indero is the ideal partner for clinical needs at global scale.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250307129954/en/

Contacts

For more information:
Valerie Coveney
Communications Specialist
Indero
vcoveney@inderocro.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SES Update on Annual General Meeting Agenda14.3.2025 21:41:00 EET | Press release

SES S.A. (“SES” or the “Company”) today issued the following statements in relation to the Company’s upcoming Annual General Meeting (“AGM”), taking place on 3 April 2025: Proposed Additions to SES’s Board of Directors The Company is pleased to propose the addition of two new members, Ellen Lord and John Shaw, to its Board of Directors. Ellen Lord is the former Under Secretary of Defense for Acquisition and Sustainment of the United States Department of Defense and has board experience with listed and non-listed companies, including Voyager Space Holdings Inc., National Defense Industrial Association and Defense Technology Initiative. John Shaw is a former Deputy Commander of the U.S. Space Force and first Commander of the USSF Space Operations Command and Combined Forces Space Component Command. The Company believes that adding the unique and valuable experience and skillsets of Ellen and John to its Board, both of whom bring direct experience in U.S. Department of Defense and U.S. Sp

bd-capital raises €430 million for Second Fund14.3.2025 11:35:00 EET | Press release

bd-capital, the pan-European, operator-led investment firm, is pleased to announce the final closing of its second fund, bd-capital Fund 2 (“Fund 2”), at €430 million. The fund closed more than 20% over its target of €350 million after less than twelve months in the market. With the closing of Fund 2, bd-capital’s assets under management have increased to over €800 million. Commitments to Fund 2 were secured from a diverse cohort of institutional investors, including insurance companies, pension funds, sovereign wealth funds and family offices. In addition to Europe and the Middle East, a significant proportion of capital came from North American investors. bd-capital’s Managing Partners, Andy Dawson and Richard Baker, said: “We are incredibly grateful for the continued support we have received from our existing limited partners and are delighted to have welcomed such a fantastic group of new investors into Fund 2. To have exceeded our fundraising target in a relatively short timeframe

Reply at NVIDIA GTC 2025: How AI Agents and Digital Humans are Redefining Customer Experience14.3.2025 11:00:00 EET | Press release

Reply, a global systems integrator and consulting firm, specialised in AI-driven solutions and intelligent systems, is taking part in NVIDIA GTC 2025, a premier conference hosted by NVIDIA that is focused on the future of accelerated computing and AI, held from March 17–21 in San Jose, California. As part of the event, Roberto Del Ponte, Associate Partner at Infinity Reply, will take the stage for an insightful panel discussion titled “Customer Service 2.0: Transforming Experiences with AI Agents and Digital Humans” on March 19, 2025, from 11:00 AM to 12:00 PM PT. The panel will explore the evolving role of AI-driven customer interactions, focusing on AI agents and digital humans. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250314195701/en/ Reply’s participation in NVIDIA GTC 2025 underscores its commitment to advancing the field of digital humans and emotionally intelligent AI solutions. (Graphic: Business Wire) The disc

Galderma Successfully Placed an Inaugural EUR 500 Million Single Tranche Eurobond and New Dual Tranche CHF 435 Million CHF Bonds14.3.2025 08:00:00 EET | Press release

Galderma Group AG (SWX:GALD): NOT FOR DISTRIBUTION IN THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE RESTRICTED BY APPLICABLE LAW OR REGULATION. Galderma (SIX: GALD) has made significant progress on its refinancing strategy to spread out its maturity profile, diversify funding sources and reduce its interest costs, by successfully issuing the following bonds: EUR 500 million bond, with a 5-year maturity and a 3.5% fixed-rate annual coupon CHF 190 million bond, with a 4-year maturity and a 1.4025% fixed-rate annual coupon CHF 245 million bond, with a 8-year maturity and a 1.8098% fixed-rate annual coupon The payment dates are March 20, 2025, for the Eurobond and the CHF bonds. The bonds will be listed on the SIX Swiss Exchange. The EUR transaction was led by BNP Paribas, J.P. Morgan, Mizuho, and Santander as active bookrunners, while the CHF transaction was led by UBS and BNP Paribas. Galderma is rated BBB (stable outlook) by Fitch and Fitch is expect

ClickHouse Acquires HyperDX to Accelerate the Future of Observability13.3.2025 17:00:00 EET | Press release

ClickHouse, the company behind the world's fastest analytical database, today announced the acquisition of HyperDX, an open-source observability platform built on ClickHouse. This strategic acquisition reinforces ClickHouse's commitment to delivering the fastest, most cost-effective, and scalable solutions to developers and enterprises worldwide; including observability. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250313954782/en/ ClickHouse, the company behind the world's fastest analytical database, today announced the acquisition of HyperDX, an open-source observability platform built on ClickHouse. (Graphic: Business Wire) The acquisition combines ClickHouse's unmatched performance and scalability with HyperDX's developer-first experience, creating a comprehensive observability platform that seamlessly integrates session replay, exceptions, logs, infrastructure metrics, and distributed tracing through an OpenTelemetry

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye